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Several cytotoxic mechanisms have been attributed to T cells participating in b-cell death in type 1 diabetes. However, sensitivity of b-cells to these mechanisms in vitro and in vivo is likely to be different. Moreover, CD4
+ and CD8 + T cells may use distinct mechanisms to cause b-cell demise that possibly involve activation of third-party cytotoxic cells. We used the transfer of genetically modified diabetogenic T cells into normal, mutant, and bone marrow chimeric recipients to test the contribution of major cytotoxic mechanisms in b-cell death. We found that 1) the killing of b-cells by CD4 + T cells required activation of the recipient's own cytotoxic cells via tumor necrosis factor-a (TNF-a); 2) CD8 + T-cell cytotoxic mechanisms destroying b-cells were limited to perforin and Fas ligand, as double knockouts of these molecules abrogated the ability of T cells to cause diabetes; and 3) individual CD8 + T-cell clones chose their cytotoxic weaponry by a yet unknown mechanism and destroyed their targets via either Fas-independent or Fas-dependent (;40% of clones) pathways. Fas-dependent destruction was assisted by TNF-a. Diabetes 61: [2862] [2863] [2864] [2865] [2866] [2867] [2868] [2869] [2870] 2012 T he cooperation between cytotoxic mechanisms used by different cell types involved in type 1 diabetes is important to understand for the therapeutic interventions in the disease progression. In type 1 diabetes, pancreatic islets are destroyed by infiltrating T cells (1) (2) (3) and their proxies, such as activated macrophages (4) . Both CD4 + and CD8 + T cells are critical for development of type 1 diabetes (1) (2) (3) 5) . Multiple death pathways were suggested to be critical in type 1 diabetes including perforin (Prf)/granzyme B, tumor necrosis factor (TNF) family receptors (Fas/CD95, TNF receptors [TNFRs], DR4), cytokines (interleukin [IL]-1 and interferon-g) (6) (7) (8) (9) (10) (11) , and oxidative damage (12, 13) . However, controversies remain that most likely result from in vitro investigation of b-cell toxicity of activated cells or cytokines. In vitro experiments reveal a potential for cytokines to kill b-cells, but their real involvement and source in vivo are not always clear. Besides, pleiotropic factors (such as Fas or TNF-a) can be involved in functions other than destruction of b-cells. Moreover, the death pathways induced by CD4 + and CD8 + T cells are very likely to be different. Indeed, CD4 + T cells were not dependent on Fas to kill b-cells in a model that used an ectopic antigen expressed in the islets (14) , whereas CD8 + T cells were shown to destroy b-cells via Fas and Prf (11, 15) .
Thus, we sought to use genetic approaches to investigate how diabetogenic CD4 + and CD8 + T cells destroy b-cells in vivo. In addition, we addressed the question of why some diabetogenic CD8 + T cell clones were reported to be heavily dependent on Fas for b-cell destruction, whereas others using the same T-cell receptor (TCR) were not (15, 16 25 mol/L b2-mercaptoethanol (Bio-Rad Laboratories, Hercules, CA), 20 mmol/L penicillin-streptomycin mixture (Invitrogen), and 3 mg/mL L-glutamine (Invitrogen). After 3 days of activation, recombinant IL-2 was added to the medium at 5 U/mL. Two days later, cells were collected (.99% of collected live cells were activated T cells), washed with PBS, and injected intravenously into retro-orbital plexus (10 7 cells/mouse) of recipient mice irradiated (7.25 Gy) to ensure more uniform induction of diabtes (17) . Both male and female recipient mice (5-9 weeks of age) were used. To show that T cells from Fas ligand (FasL), Prf, and TNF triple-deficient mice were homing normally to the islets, activated T cells were labeled with a fluorescent dye and injected into mice, and pancreata were fixed, frozen in OCT compound (Sakura Finetek USA, Torrance, CA), sectioned, and examined as described (17, 19 For the high-throughput testing, the effector to target cell (E:T) ratios were not determined for every clone, but they were similar. Microarray analysis. RNA isolated from three samples of peptide-activated, IL-2-rested G9C8 clone and transgenic male mice (on NOD background to avoid drastic allelic differences in gene expression) were hybridized to Affymetrix Mouse 430v2.0 GeneChips (Affymetrix). Affymetrix GCOS software (Affymetrix) was used to run the comparison analysis method using default parameters, with signal scaling (target value = 150) to normalize signal from each chip. Resulting files were subjected to further analysis using GeneSpring GX7.3 (Agilent Technologies) and Ingenuity Pathway Analysis software. The microarray data have been deposited in the National Center for Biotechnology Information's Gene Expression Omnibus (21) and are accessible through Gene Expression Omnibus Series accession number GSE31726 (http://www.ncbi. nlm.nih.gov/geo/query/acc.cgi?acc=GSE31726). Statistical analysis. Statistical significance was determined using the Student t test, Mann-Whitney test, or Kaplan-Meier survival analysis using GraphPad Prism (version 4.0c for Macintosh; GraphPad). Error bars represent SE.
RESULTS

CD4
+ T-cell-mediated islet destruction is independent of FasL or Prf but depends on TNF-a. Because insulinproducing cells are negative for MHC class II molecules, direct contact of CD4 + T cells with b-cells is likely not required for their destruction. Previous reports using transfer of diabetogenic BDC2.5 CD4 + T cells supported this idea by showing indirect (4) and MHC class II-independent (22) destruction of the islets by the CD4 + T cells. However, the signaling pathways leading to activation of the cytotoxic intermediates and the actual cytotoxic mechanisms involved in islet destruction are not clearly defined. To address this issue, we tested several cytotoxic receptors for their involvement in killing of b-cells by activated CD4 + T cells or their proxies.
In the first experiment, Fas receptor-deficient B6. H2 (Fig. 1A) . To make sure that complete Fas deficiency in the recipient did not produce an artificial enhancement of cytotoxic activity of the cells causing b-cell death, we injected BDC2.5 cells into NOD recipients lacking Fas specifically in b-cells due to the Cre-mediated deletion of floxed Fas (NOD.FasKi.Rip-Cre3) (23, 24) . Diabetes induction in these mice was no different from control recipients (Fig. 1B) (Fig. 1D) . Thus, TNF-a was the major factor that participated in b-cell destruction by CD4 + T cells. TNF-a does not require direct contact of CD4 + T cell with b-cells in order to be produced and can be secreted subsequent to T cell recognition of a b-cell antigen presented by an antigenpresenting cell (APC). Thus, it was equally possible that TNF-a was directly cytotoxic to b-cells or worked as a mediator to induce another cytotoxic mechanism in a third-party cell. TNF-a produced by CD4 + T cells is not directly cytotoxic to b-cells. To address the role of TNF-a in killing of b-cells by CD4 + T cells, we produced NOD→ NOD.TNFR1/2 KO bone marrow chimeras and injected them with BDC2.5 CD4 + T cells. The bone marrow-derived TNFR-sufficient cells completely restored the ability of BDC2.5 CD4 + T cells to induce diabetes ( Fig. 2A) . Thus, it became clear that TNF-a is not involved in direct destruction of b-cells because recipient's b-cells did not have receptors for it. Instead, TNF-a was required to activate other cell types (of bone marrow origin) that then killed b-cells. Because the two TNFRs differ in function (25, 26) , we tested which of the receptors was involved in b-cell destruction. Diabetes induction in NOD.TNFR1
2/2 or control mice was comparable upon transfer of activated BDC2.5 CD4 + T cells (Fig. 2B) . A slight delay was observed in NOD.TNFR2
2/2 recipients compared with NOD mice, but this delay was not as strong as the delay observed in NOD.TNFR1/2 KO mice (Fig. 2) . Thus, TNF-amediated signals involved in activation of intermediaries seem to be transduced via both TNFR1 and TNFR2. Because transfer of activated BDC2.5 CD4 + T cells into NOD.TNFR1/2 KO mice delayed but did not abolish type 1 diabetes development, a contribution of another yet unknown factor involved in b-cell destruction by CD4 + T cells can be predicted. Cytotoxic pathways used by diabetogenic CD8 + T cells. CD8 T cells can kill their targets upon direct contact or produce cytotoxic cytokines. Previous reports (15, (27) (28) (29) support the idea that cytotoxic mechanisms involving direct contact with the target cells (b-cells) are important. At the same time, cytokines, such as TNF-a, IL-1, and interferon-g were cytotoxic to b-cells (9, 10, 29) . Using transfer of genetically modified activated CD8 + T cells, we sought to establish the importance of the major cytotoxic mechanisms.
We took advantage of TCR-transgenic mice carrying a TCR from a CD8 + T-cell clone G9C8 (17) (Fig. 3B) . Together, these data indicated that Prf, FasL, and TNF-a composed the minimal group of effector cytokine pathways required for induction of diabetes by activated insulin-specific CD8 + T cells. The conclusion also implies that no other factors acting independently of the trio are by themselves capable of b-cell destruction.
These cytotoxic pathways could be redundant, or perform unique functions. Thus, we tested combinations of these three deficiencies. (Fig. 3D) or both Prf-and TNF-a-mediated killing (Fig. 3E ).
These results demonstrate that cytotoxic CD8 + T cells can use either Prf-or FasL-mediated killing to cause destruction of pancreatic islets, and both pathways can fully compensate for the absence of the other. Moreover, in this experimental setting, TNF-a seemed to be completely dispensable ( Fig. 3C-E (Fig. 4B) . Therefore, it became evident that in vivo cytotoxicity of the G9C8 clone was highly dependent on the Fas-FasL pathway, which was not the case for the functionally polyclonal G9C8-transgenic T cells. Because the clone and transgenic T cells shared the G9C8 TCR, it was evident that their antigen specificity was not relevant to the differences in their cytotoxic properties. These differences could be due to long-term in vitro cultivation of the clone or may be explained by intrinsic properties of individual clones. To address this, we used an in vitro cytotoxicity assay to simultaneously test multiple T-cell clones. Whereas the G9C8 clone failed to destroy Fas-negative targets (Fig. 4C) , killing by G9C8 TCR-transgenic T cells was only slightly reduced (proportionally to E:T ratios tested). Importantly for data interpretation, the killing of B6.K d and NOD targets was similar (Fig. 4D) . We then generated multiple single-cell clones from activated B6.K d G9C8 T cells by limiting dilution. Most of the 71 clones tested displayed reduced killing of B6.K d lpr/lpr targets and an only marginally compromised killing of NOD.TNFR1/2 KO targets, indicating that FasL and, to a significantly lesser extent, TNF-a were essential for the strong in vitro target lysis (Fig. 5A) . Because the low maximal killing of the wildtype targets by some clones could affect quantitative assessments, we compared 27 clones with target killing of .40%. Fourteen out of 27 clones showed substantially reduced killing of B6.K d lpr/lpr targets (Fig. 5B ). This pattern was very similar to that displayed by the G9C8 clone in a target killing assay (Fig. 4C) . Thus, ;40% of T-cell clones that have been in culture for only a short period of time (compared with years in culture for the original G9C8 clone) demonstrated a similar phenotype: dependence on Fas. To test whether this phenotype is stable, several original clones were subcloned and their cytotoxic properties determined. The subclones were more homogenous with fewer variations in their killing efficiency. Subclones of clone 23 and clone 19 displayed markedly lower killing of B6.K d lpr/lpr as compared with NOD.TNFR1/2 KO or NOD targets, consistent with the properties of parental clones (Fig. 5C) . Subclones of another clone (13, not shown) displayed two types of reactivity (one with high lysis and another with low lysis of lpr/lpr targets); however, we cannot exclude the possibility that the original culture contained two clones. Contribution of TNF-a to type 1 diabetes induction by the CD8 + T cells. Although TNF-a seemed to be dispensable for killing of b-cells by G9C8 TCR-transgenic T cells, the G9C8 clone exclusively depended on FasLmediated killing. We sought to determine whether under such conditions TNF-a signaling could play a role. When G9C8 clone cells were transferred into NOD.TNFR1/2 KO recipients, diabetes development was significantly delayed, and only 75% of the mice eventually developed the disease, compared with wild-type controls, all of which succumbed by day 8 posttransfer (Fig. 6A) . The transfer of the G9C8 clone cells into NOD.TNFR2 2/2 single-KO recipients induced diabetes with kinetics similar to that of control TNFR-sufficient recipient mice (Fig.  6A) , suggesting that signaling through this receptor was not important. In contrast, NOD.TNFR1 2/2 mice were far less sensitive to G9C8 clone (Fig. 6A) . This is different from what we have observed with the transfer of the BDC2.5 CD4 + T cells (Fig. 2B) , in which the two receptors had redundant function. At the same time, in an in vitro cytotoxicity assay, G9C8 clone cells killed NOD.TNFR1/2 KO and NOD spleen cell targets with equal efficiency, indicating a lack of dependence on TNFR signaling in this context (Fig. 4C) .
We then compared mRNA and protein expression of the cytotoxic molecules between G9C8 clone and G9C8 TCRtransgenic T cells activated under similar conditions. The G9C8 clone displayed a twofold higher level of TNF-a transcript and higher protein expression (Fig. 6B and C) , whereas the levels of FasL were only slightly higher, and no differences in Prf expression were found.
Taken together, these results suggest that TNF-a--mediated signaling is required to facilitate FasL-mediated destruction of b-cells in vivo and that chronically activated T cells acquire different physiological properties including killing mechanisms. 
DISCUSSION
The genetic approach used in this study allowed us to make several important observations concerning the role of cytotoxic mechanisms involved in destruction of insulin-producing cells. + T cells (14) . However, the lack of TNF-a signaling in the recipient significantly delayed the induction of type 1 diabetes (Fig.  1C) , which was not further affected by the combined deletion of Prf and FasL (Fig. 1D ). TNF-a is a cytokine with a range of activities important in diabetes development, including upregulation of cell adhesion by endothelial cells promoting homing of leukocytes (37) (38) (39) , upregulation of MHC class I and II expression by islets (40, 41) , activation of APCs and T cells, and direct killing of b-cells in vitro has been shown (42) . However, this cytokine produced by activated CD4 + T cells did not kill b-cells in vivo directly; type 1 diabetes development in TNFR-negative recipients was restored when bone marrow-derived cells were replaced with TNFR-sufficient cells (Fig. 2A) . Taken together, the results of the studies of diabetogenic CD4 + T cells lead to three conclusions: 1) TNF-a works as an inducer of cytotoxic capabilities in a third-party cell; 2) activation of third-party cells through Fas, which can work as activating molecule (43), does not happen or is not important; and 3) possible killing (through Fas) of islet APCs within the islets is not critical for the third-party cell-mediated destruction of b-cells.
Interestingly, TNFR1 and TNFR2 (to a slightly lesser degree) were important for CD4 + T cell-dependent induction of cytotoxicity (Fig. 2B) . TNFR1 is considered to be proapoptotic and has been shown to be important for TNF-a-mediated destruction of islets in an allogenic islet transplant model (8) . For the induction of cytotoxicity in a third-party cell, TNF-a provided activating signaling through both of its receptors. Macrophages (4) or other cell types such as dendritic cells and natural killer cells can be the third-party killers. All three cell types can be activated by TNF-a, and further investigation is required to put the responsibility for killing of b-cells on one (or all) of these subsets.
TNF-a produced by CD8 + T cells can be directly cytotoxic, although the importance of this was not supported by our experiments (Fig. 3C) . It may also play a role (similar to CD4 + T cell-derived TNF-a) in the activation of thirdparty cytotoxic cells. This became apparent in experiments using the G9C8 clone. The clone used FasL to kill b-cells and in vitro killing of target cells was TNF-a-independent , and NOD.TNFR1/2 KO mice mixed 1:1 with differentially labeled B6 control cells in the presence of 5 mg/mL of InsB 15223 peptide and used at indicated E:T ratios. Sixteen hours later, cells were isolated, and survival of specific targets relative to survival of the control B6 cells was estimated to determine specific lysis. Data represent mean + SEM of three replicate samples at each E:T ratio. P values for curves were found using Kaplan-Meier statistics. *P < 0.05, **P < 0.005. (Fig. 4C) . At the same time, the induction of type 1 diabetes was delayed in NOD.TNFR1/2 KO recipients (Fig.  6A) . Interestingly, the delay in disease development was entirely dependent on TNFR1 and not on TNFR2 (Fig. 6A) . This difference with CD4 + T cells could also mean that TNF-a is capable of facilitation of Fas expression by b-cells (which is inherently low on these cells without activation) (44, 45) or of sensitivity of target cells to its engagement. TNFR1 has been implicated in the development of spontaneous type 1 diabetes (46) , and in our hands, NOD. TNFR1/2 KO mice were also completely protected from spontaneous diabetes (incidence of zero out of nine) for the 30 weeks of observation.
Our report on the role of Fas in type 1 diabetes development (7) induced a long-lasting discussion with experimental evidence both pro (29, 47) and against (32, 48) participation of Fas in b-cell destruction. Involvement of other cytotoxic molecules in b-cell destruction has been suggested. Preferential use of Prf, for example, was linked to TCR affinity and the age of animals (49) .
Thus, we addressed the controversial issues using a genetic approach. We have learned that Fas and Prf are both important, and each of them can kill b-cells on their own. Another important conclusion is that (at least in the transfer model, in which all other in vivo requirements for T cell activation are bypassed) the list of cytotoxic mechanisms used by CD8 + T cells can be reduced to just two, FasL-and Prf. Other mechanisms can be involved, but they must play an accessory role, whereas FasL or Prf is necessary.
One unresolved problem involving our initial work was that whereas G9C8 clone failed to cause diabetes in NOD lpr/lpr mice (7), T cells derived from a transgenic mouse with the same TCR successfully induced the disease (Fig. 4B) . TCR-transgenic T cells are monospecific, but polyclonal in all other aspects. Thus, the G9C8 clone could have been unique in losing its ability to kill via Prf, or individual T cells from the transgenic mouse varied in which weapon they chose. Among highly cytotoxic T-cell clones derived from G9C8-transgenic mice, ;40% failed to destroy Fas-negative targets. These clones were in culture for about 25 days (compared with the original G9C8 clone that had been in culture for many years), suggesting that the decision to forgo Prf-mediated killing was made rather early. Moreover, these clones were stable, as the secondary clones reproduced the phenotype of the original clones. These results argue that individual clones of T cells vary in their preferred cytotoxic mechanisms. Interestingly, expression of the Prf-encoding Prf1 gene was not different between the G9C8 clone and activated T cells from G9C8 TCR-transgenic (Fig. 6B) . Thus, the regulation of cytotoxicity must be posttranslational. The choice of cytotoxic pathway used by a given T cell could be stochastic or inducible by external signals, which is an interesting issue warranting further investigation. Another diabetogenic CD8
+ T-cell clone, 8.3, has been shown to destroy b-cells via a FasL-mediated mechanism, although non-b-cell targets were killed by a different mechanism by the same cells (16) . Thus, there may be other factors that aid destruction of specific cell types by different cytotoxic mechanisms.
These complementary mechanisms and the actual mechanism(s) of b-cell killing by secondary effectors need to be elucidated in future experiments because of their potential importance as targets for therapeutic intervention in type 1 diabetes.
